Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
J Addict Med. 2022;16(1):e8-e15. doi: 10.1097/ADM.0000000000000813.
The novel 2019 coronavirus (COVID-19) crisis has caused considerable upheaval in the U.S. healthcare system. The current study examined patient-reported experiences in substance use disorder (SUD) treatment during the early stages of the COVID-19 crisis.
Participants in SUD treatment were recruited via online crowdsourcing from April 14, 2020 to May 26, 2020, during the early stages of the COVID-19 crisis. Participants reported disruptions in SUD treatment, stress and anxiety caused by these disruptions on a 0-100 point visual analogue scale (VAS), stress associated with childcare responsibilities on a 0-100 VAS, current stress on the Perceived Stress Scale (PSS), anxiety symptoms on the Beck Anxiety Inventory (BAI), sleep disturbances on the Insomnia Severity Index (ISI), and whether they used drugs or alcohol during the COVID-19 crisis.
Participants (N = 240) endorsed that at least 1 SUD treatment was switched to telemedicine (63.7%), had some appointments cancelled (37.5%), or was discontinued due to COVID-19 (29.6%). Participants who did versus did not endorse drug/alcohol use reported difficulty obtaining medications to treat their SUD (OR = 2.47, 95% CI, 1.17-5.22, χ2 = 5.98, P = .016), greater scores on VAS treatment-related stress (F1,197 = 5.70, P = .018) and anxiety (F1,197 = 4.07, P = .045), greater VAS stress related to childcare (F1,107 = 10.24, P = .002), and greater scores on the PSS (F1,235 = 19.27, P < .001), BAI (F1,235 = 28.59, P < .001), and ISI (F1,235 = 14.41, P < .001).
Providers and public health officials should work to improve continuity and quality of care during the COVID-19 crisis, with special attention on addressing childcare difficulties and providing remote methods to improve stress, anxiety, and sleep for persons in SUD treatment.
新型 2019 冠状病毒病(COVID-19)危机给美国医疗体系带来了巨大动荡。本研究旨在探讨 COVID-19 危机早期物质使用障碍(SUD)治疗中患者报告的体验。
2020 年 4 月 14 日至 2020 年 5 月 26 日,在 COVID-19 危机早期,通过在线众包从 SUD 治疗中招募参与者。参与者使用 0-100 点视觉模拟量表(VAS)报告 SUD 治疗中断、这些中断引起的压力和焦虑、与儿童保育责任相关的 0-100 VAS 压力、当前压力感知量表(PSS)、贝克焦虑量表(BAI)上的焦虑症状、失眠严重指数(ISI)上的睡眠障碍,以及他们在 COVID-19 危机期间是否使用药物或酒精。
参与者(N=240)表示至少有 1 种 SUD 治疗转为远程医疗(63.7%),部分预约取消(37.5%),或因 COVID-19 而中断(29.6%)。与未报告药物/酒精使用的参与者相比,报告药物获取困难以治疗 SUD 的参与者(OR=2.47,95%CI,1.17-5.22,χ2=5.98,P=0.016),VAS 治疗相关压力(F1,197=5.70,P=0.018)和焦虑(F1,197=4.07,P=0.045)评分更高,VAS 与儿童保育相关的压力(F1,107=10.24,P=0.002)更大,PSS(F1,235=19.27,P<0.001)、BAI(F1,235=28.59,P<0.001)和 ISI(F1,235=14.41,P<0.001)评分更高。
提供者和公共卫生官员应努力在 COVID-19 危机期间改善护理的连续性和质量,特别关注解决儿童保育困难,并提供远程方法来改善 SUD 治疗者的压力、焦虑和睡眠。